RESUMO
We have developed an integrase-defective lentiviral (LV) vector in combination with a gene-targeting approach for gene therapy of ß-thalassemia. The ß-globin gene-targeting construct has two homologous stems including sequence upstream and downstream of the ß-globin gene, a ß-globin gene positioned between hygromycin and neomycin resistant genes and a herpes simplex virus type 1 thymidine kinase (HSVtk) suicide gene. Utilization of integrase-defective LV as a vector for the ß-globin gene increased the number of selected clones relative to non-viral methods. This method represents an important step toward the ultimate goal of a clinical gene therapy for ß-thalassemia.
Assuntos
Marcação de Genes/métodos , Vetores Genéticos , Lentivirus/genética , Globinas beta/genética , Antibacterianos/farmacologia , Cinamatos/farmacologia , Terapia Genética/métodos , Herpesvirus Humano 1/enzimologia , Higromicina B/análogos & derivados , Higromicina B/farmacologia , Integrases/deficiência , Neomicina/farmacologia , Recombinação Genética , Seleção Genética , Homologia de Sequência , Timidina Quinase/metabolismo , Talassemia beta/terapiaRESUMO
OBJECTIVE: Obesity is a risk factor for the development of insulin resistance and is one of the most important contributors to the pathogenesis of type 2 diabetes, which acts mainly through the secretion of adipokines such as TNF-α that may influence insulin sensitivity. TNF-α affects many aspects of adipocyte function, such as adipocyte development and lipid metabolism. MATERIAL AND METHODS: We demonstrated that there is a correlation between the expressions of TNF-α in retroperitoneal WAT and insulin-resistance in 8 genetically obese fa/fa rats. Treatment of animals with CL 316,243, a ß3-adrenergic agonist, showed an improvement of insulin-resistance that was linked with the suppression of TNF-α mRNA expression in WAT. RESULTS: These results confirm the association between TNF-α expression and the insulin-resistant condition in rats. Our finding indicates that the hyperglycaemia and hyperinsulinemia induced by insulin-resistance correlated positively with the expression of TNF-α mRNA in an abdominal WAT depot. CONCLUSION: We conclude that CL 316,243 possesses both anti-diabetic effects and anti-obesity effects in rodents.
Assuntos
Dioxóis/farmacologia , Regulação para Baixo/efeitos dos fármacos , Hipoglicemiantes/farmacologia , Fator de Necrose Tumoral alfa/genética , Gordura Abdominal/efeitos dos fármacos , Gordura Abdominal/metabolismo , Tecido Adiposo Branco/efeitos dos fármacos , Tecido Adiposo Branco/metabolismo , Agonistas Adrenérgicos beta/farmacologia , Animais , Glicemia/metabolismo , Northern Blotting , Peso Corporal/efeitos dos fármacos , Peso Corporal/genética , Ácidos Graxos/sangue , Expressão Gênica/efeitos dos fármacos , Insulina/sangue , Resistência à Insulina/genética , Masculino , Obesidade/sangue , Obesidade/genética , Obesidade/prevenção & controle , Ratos , Ratos Zucker , Receptores Adrenérgicos beta 3/metabolismoRESUMO
BACKGROUND: Recombinant human erythropoietin (rhEPO) is considered to be one of the most pivotal pharmaceutical drugs in the market because of its clinical application in the treatment of anemia-associated disorders worldwide. However, like other therapeutic proteins, it does not have suitable pharmacokinetic properties for it to be administrated at least two to three times per week. Chemoselective cysteine PEGylation, employing molecular dynamics and graphics in in silico studies, can be considered to overcome such a problem. METHODS: A special kind of EPO analog was elicited based on a literature review, homology modeling, molecular dynamic simulation, and factors affecting the PEGylation reaction. Then, cDNA of the selected analog was generated by site-directed mutagenesis and subsequently cloned into the expression vector. The construct was transfected to Chinese hamster ovary/dhfr(-) cells, and highly expressed clones were selected via methotrexate amplification. Ion-immobilized affinity and size exclusion (SE) chromatography techniques were used to purify the expressed analog. Thereafter, chemoselective PEGylation was performed and a nanosize PEGylated EPO was obtained through dialysis. The in vitro biologic assay and in vivo pharmacokinetic parameters were studied. Finally, E31C analog Fourier transform infrared, analytical SE-high-performance liquid chromatography, zeta potential, and size before and after PEGylation were characterized. RESULTS: The findings indicate that a novel nanosize EPO31-PEG has a five-fold longer terminal half-life in rats with similar biologic activity compared with unmodified rhEPO in proliferation cell assay. The results also show that EPO31-PEG size and charge versus unmodified protein was increased in a nanospectrum, and this may be one criterion of EPO biologic potency enhancement. DISCUSSION: This kind of novel engineered nanosize PEGylated EPO has remarkable advantages over rhEPO.
Assuntos
Cisteína/química , Eritropoetina/química , Nanopartículas/química , Polietilenoglicóis/química , Animais , Células CHO , Linhagem Celular , Proliferação de Células , Cromatografia em Gel , Clonagem Molecular , Simulação por Computador , Cricetinae , Cricetulus , Cisteína/genética , Cisteína/metabolismo , Sistemas de Liberação de Medicamentos , Eritropoetina/genética , Eritropoetina/metabolismo , Eritropoetina/farmacocinética , Ácido Glutâmico/genética , Humanos , Metotrexato/farmacologia , Simulação de Dinâmica Molecular , Mutagênese Sítio-Dirigida , Ligação Proteica , Estabilidade Proteica , Proteínas Recombinantes , Espectroscopia de Infravermelho com Transformada de FourierRESUMO
Metabolic imaging is commonly performed by nuclear medicine facilities such as PET or SPECT, etc. The production and biomedical applications of bio-molecular sensing in vivo MRI metabolic contrast agents has recently become of great universal research interest, which follows its great success as a potential cost effective, less radioactive, nuclear medicine alternative. Temperature, redox potential, enzyme activity, free radial/metal ion responsive and/or pH sensitive molecular metabolic MR contrast agents are among the famous instances exemplified, which basically promote MR image contrast enhancement ability to distinguish molecular metabolic/gene expression features. Overall, these MRI contrast agents provide a framework to achieve a greater degree of accuracy from MRI as a low cost, more available facility, non radioactive radiation producing and highly sensitive biomedical tool to propound as a new suggesting opponent for PET nuclear medicine imaging. In the present review, the design, development, examination and future of the above agents will be discussed in detail.